Ronald B. Moss
Director/Board Member at Biosortia Pharmaceuticals, Inc.
Net worth: 150 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ross O. Youngs | M | - |
Biosortia Pharmaceuticals, Inc.
 Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | 16 years |
| Howard Birndorf | M | 74 | 5 years | |
| Peter Wendell | M | 73 | 21 years | |
| David R. Coho | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Vickie Reed | F | 62 | 2 years | |
| Meera Desai | M | 45 | 3 years | |
| John A. Ryals | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Henry Joseph Cialone | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| James Matteucci | M | - | 21 years | |
| Douglas Poling | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Derrell Porter | M | 53 |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dennis J. Carlo | M | 80 |
Telos Pharmaceuticals LLC
Orchestra Therapeutics, Inc.
 Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 34 years |
| Richard Kogan | M | 81 | 21 years | |
| Fred Hassan | M | 78 | 6 years | |
| Robert O. Hopkins | M | 63 | 14 years | |
| Ismail Kola | M | 67 | 4 years | |
| Larry W. Granatelli | M | - |
Stony Brook University
| 6 years |
| John N. Bonfiglio | M | 69 |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 2 years |
| David Anstice | M | 75 | 5 years | |
| Roshawn Blunt | F | 49 | 2 years | |
| Mark Flather | M | - | 8 years | |
| Jeffrey Sachs | M | - |
Stony Brook University
| 8 years |
| William C. Denby | M | 69 | 5 years | |
| Robert B. Rothermel | M | 80 | 5 years | |
| Tony Chiarenza | M | - |
Stony Brook University
| 4 years |
| Rosemary Dehlow | F | - |
Stony Brook University
| 4 years |
| Eduardo O. Thompson | M | - | 6 years | |
| Pradeep K. Wahi | M | - |
Stony Brook University
| 4 years |
| Simon D. Kelner | M | 51 | 13 years | |
| Egil Bodd | M | 69 | 11 years | |
| Bruce A. Deitchman | M | - |
Stony Brook University
| 4 years |
| Jane Anne Salik | M | 71 |
Stony Brook University
| 3 years |
| Bing Chan | F | - |
Stony Brook University
| 4 years |
| Robert W. Verdugo | M | - | 3 years | |
| David Feinberg | M | 61 |
Chicago Medical School
| 4 years |
| Sheldon R. Reich | M | 66 |
Stony Brook University
| 3 years |
| Andrew R. de Guttadauro | M | 57 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 years |
| Manal Morsy | M | - | 9 years | |
| Mitch L. Levin | M | - |
Stony Brook University
| 4 years |
| Dalei Shao | M | - | 2 years | |
| Joseph H. McKenna | M | - |
Stony Brook University
| 4 years |
| Pieter H. Smit | M | - |
Stony Brook University
| 4 years |
| Eric Greenspan | M | - |
Stony Brook University
| 5 years |
| Yaacov Weinstock | M | - | 1 years | |
| Michael James Cash | M | - |
Stony Brook University
| 3 years |
| Michael Foley | M | 66 |
Chicago Medical School
| 4 years |
| David Ege | M | 50 | 16 years | |
| Gary Goldman | M | - |
Stony Brook University
| 4 years |
| Judith C. Seltz | F | 61 | 15 years | |
| Robert Hansen | M | - |
Stony Brook University
| 3 years |
| Bob Moore | M | - |
Stony Brook University
| 2 years |
| Kenneth Peter Steinmetz | M | - |
Stony Brook University
| 4 years |
| Richard Napolitano | M | - |
Stony Brook University
| 5 years |
| Nancy Thornberry | F | 67 | 9 years | |
| Corey S. Kupfer | M | - |
Stony Brook University
| 4 years |
| Hüseyin Bayazit | M | 65 |
Stony Brook University
| 4 years |
| John Yates | M | 67 | 13 years | |
| Paul Marcotrigiano | M | - |
Stony Brook University
| 4 years |
| Richard E. Aiello | M | - |
Stony Brook University
| 4 years |
| Gerald L. Wisler | M | 67 | 20 years | |
| Wendy Perrow | F | 66 | 14 years | |
| James Christopher Scalet | M | 65 | 9 years | |
| George P. Vlasuk | M | - |
Stony Brook University
| 2 years |
| Martyn D. Greenacre | M | 82 |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 5 years |
| Emmanuel Lakios | M | 62 |
Stony Brook University
| 4 years |
| Mark A. Burnett | M | 64 |
Stony Brook University
| 4 years |
| Richard M. Bartholomew | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | - |
| Peter Lowry | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | - |
| Mark A. Varney | M | 57 | 4 years | |
| Willie Deese | M | 68 | 12 years | |
| William Daley | M | 75 | 4 years | |
| Rahul Singhvi | M | 59 | 5 years | |
| Patrick Yang | M | 75 | 11 years | |
| Young C. McGuinn | F | 64 | 6 years | |
| David Arkowitz | M | 62 | 3 years | |
| Stephen Gold | M | 65 | 2 years | |
| Paul Howes | M | 69 | 5 years | |
| Gregory Butler | M | 66 |
Stony Brook University
| 4 years |
| Jeffrey Lightcap | M | 66 |
Stony Brook University
| 4 years |
| Glenn Dubin | M | 67 |
Stony Brook University
| - |
| Steven Richieri | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 8 years |
| Steven Nichtberger | M | 62 | 8 years | |
| Russell B. Brown | M | - |
Stony Brook University
| 4 years |
| Bill Hayde | M | 59 |
Stony Brook University
| 4 years |
| Christopher Duffy | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 12 years |
| Cono A. Carrano | M | - |
Stony Brook University
| 4 years |
| Howard Chin | M | - | 1 years | |
| Thomas Martin Vernon | M | 85 | - | |
| Bernard J. Kelley | M | 82 | 10 years | |
| Wai Lam | M | - |
Stony Brook University
| 4 years |
| Alan S. Rosenthal | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 6 years |
| David King | M | 65 |
Stony Brook University
| 2 years |
| Ian M. Miller | M | - | 11 years | |
| David H. Langsam | M | - |
Stony Brook University
| 4 years |
| Steven I. Traum | M | - |
Stony Brook University
| 4 years |
| Linda Burns | F | - | 1 years | |
| Guy MacDonald | M | 65 | 22 years | |
| Ben Shapiro | M | 84 | 13 years | |
| Joseph C. Zinghini | M | - |
Stony Brook University
| 4 years |
| Joe Rosen | M | - |
Stony Brook University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ronald B. Moss
- Personal Network
